Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma – Lessons From Individual Cases With Long-Term Follow-Up

BACKGROUND: The tyrosine kinase inhibitors (TKI) vandetanib and cabozantinib are approved as targeted therapies in advanced medullary thyroid carcinoma (MTC) with symptoms or high tumour burden. Only recently, toxicity in long-time TKI usage was analysed. However, little is known about the impact of...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandenburg, Tim, Tiedje, Vera, Muchalla, Philipp, Theurer, Sarah, Weber, Frank, Schmid, Kurt Werner, Dralle, Henning, Führer, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511790/
https://www.ncbi.nlm.nih.gov/pubmed/34659114
http://dx.doi.org/10.3389/fendo.2021.718418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511790/
https://www.ncbi.nlm.nih.gov/pubmed/34659114
http://dx.doi.org/10.3389/fendo.2021.718418

Ejemplares similares